Skip to main content
. Author manuscript; available in PMC: 2022 Jul 13.
Published in final edited form as: Cancer. 2009 Oct 1;115(19):4636–4644. doi: 10.1002/cncr.24499

Table 2.

Tumor and Treatment Characteristics of Abstainers and Continued Smokers

Abstainers, n=517 Continued Smokers, n=533
Variable No. % No. % P *
Site of primary tumor
Nasopharynx 0 0 1 3 .87
Oropharynx 11 64.7 20 60.6
Hypopharynx 1 5.8 3 9.1
Larynx 5 29.4 9 27.3
Tumor grade/differentiation
Well/moderately well 2 11.8 3 9.1 .53
Moderate 7 41.1 17 51.5
Poor/moderately poor 7 41.1 8 24.2
Tumor classification
T0-T2 7 41.1 18 54.5 .37
T3-T4 10 58.9 15 45.5
Lymph node status
N0 5 29.4 11 33.3 .78
N1-N3 12 70.6 22 66.7
Overall stage
I 2 11.8 4 12.1 .44
II 0 0 4 12.1
III 5 29.4 6 18.1
IV 10 58.8 19 57.7
Treatment
XRT alone 7 41.1 10 30.3 .57
Ind. CTX→XRT 0 0 3 9.1
Concurrent CTX-XRT 7 41.1 15 45.5
Ind. CTX→CTX-XRT 3 17.8 5 15.1
No CTX 7 41.1 10 30.3 .44
Received CTX 10 58.8 23 69.7
Variable Mean ± SD Median (Range) Mean ± SD Median (Range) P
Radiation dose, Gy 68.3 ± 3.3 70 (63–72) 68.9 ± 4.3 70 (48–72) .65
No. of radiation fractions 32.9 ± 3.17 33 (30–42) 33.2 ± 5.0 33 (12–42) .84
Radiation schedule, d 44.2 ± 4.3 44 (39–51) 43.9 ± 2.9 44 (38–51) .40
Follow-up, d 533.4 ± 227.4 519 (103–1026) 515.8 ± 395.0 395.7 (111–1210) .60

XRT indicates radiation therapy; CTX, chemotherapy; Ind., induction; SD, standard deviation; Gy, grays.

*

The chi-square or the Fisher exact test was used for categorical variables, as appropriate, and t tests were used to compare means (with adjustment for unequal variances, as appropriate) for continuous variables.

Includes 1 patient who had cervical metastasis of unknown primary origin. Radiation fields for this patient were consistent with oropharyngeal fields.

Tumor grade was not recorded for 1 abstainer and for 5 continued smokers; moderately to well differentiated was listed as well differentiated, and moderately to poorly differentiated was listed as poorly differentiated.